Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.43 |
| ▸ | ITGAL | P20701 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469298 | 1.00 | ECE1 (0.46) | ECE1ITGB2ICAM1ITGALCA2 | |
| Water SCHEMBL31495128 | 0.98 | ECE1 (0.44) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL14071766 | 0.83 | ECE1 (0.44) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL22106724 | 0.83 | ECE1 (0.44) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL14625014 | 0.82 | GNPAT (0.51) | CA2CA1GNPAT | |
| SCHEMBL8601335 | 0.82 | ECE1 (0.47) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL7080110 | 0.82 | GNPAT (0.51) | CA2CA1GNPAT | |
| SCHEMBL6558713 | 0.82 | GNPAT (0.51) | CA2CA1GNPAT | |
| SCHEMBL29742771 | 0.82 | ECE1 (0.47) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL1009371 | 0.80 | ECE1 (0.50) | ECE1ITGB2ICAM1ITGALCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115156-A1 | FC-ENGINEERED ANTI-HUMAN IGE ANTIBODIES AND METHODS OF USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-04-22 | — | — | US | claimed |
| EP-3774925-A1 | FC-ENGINEERED ANTI-HUMAN IGE ANTIBODIES AND METHODS OF USE | Institut national de la santé et de la recherche médicale (INSERM) (FR) | 2021-02-17 | — | — | EP | claimed |
| WO-2019197607-A1 | FC-ENGINEERED ANTI-HUMAN IGE ANTIBODIES AND METHODS OF USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-10-17 | — | — | WO | claimed |
| CN-108064271-A | Methylotrophic Bacillus strain and the method that plant drought resistance is improved using the bacterial strain | 皇家学术促进会麦吉尔大学 | 2018-05-22 | — | — | CN | claimed |
| US-20170226598-A1 | A BACILLUS METHYLOTROPHICUS STRAIN AND METHOD OF USING THE STRAIN TO INCREASE DROUGHT RESISTANCE IN A PLANT | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-08-10 | — | — | US | claimed |
| EP-3191579-A1 | A BACILLUS METHYLOTROPHICUS STRAIN AND METHOD OF USING THE STRAIN TO INCREASE DROUGHT RESISTANCE IN A PLANT | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2017-07-19 | — | — | EP | claimed |
| WO-2016011562-A1 | A BACILLUS METHYLOTROPHICUS STRAIN AND METHOD OF USING THE STRAIN TO INCREASE DROUGHT RESISTANCE IN A PLANT | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-01-28 | — | — | WO | claimed |
| CN-103374058-A | Solid-phase synthesis process of angiotensinamide as well as intermediate and application thereof | SHANGHAI NO 1 BIOCHEMICAL & PHARMACEUTICAL CO LTD | 2013-10-30 | — | — | CN | claimed |
| US-20240076410-A1 | FC-ENGINEERED ANTI-HUMAN IGE ANTIBODIES AND METHODS OF USE | INSTITUT PASTEUR (FR) | 2024-03-07 | — | — | US | disclosed |
| US-20210115156-A1 | FC-ENGINEERED ANTI-HUMAN IGE ANTIBODIES AND METHODS OF USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-04-22 | — | — | US | disclosed |
| EP-3774925-A1 | FC-ENGINEERED ANTI-HUMAN IGE ANTIBODIES AND METHODS OF USE | Institut national de la santé et de la recherche médicale (INSERM) (FR) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020244570-A1 | PORPHIN PHOTOSENSITIZER TARGETING FOLIC ACID AND COUPLED TO DIFFERENT CONNECTION CHAINS AND SYNTHESIS AND APPLICATION OF PORPHIN PHOTOSENSITIZER | 康宏耀源（天津）科技有限公司 | 2020-12-10 | — | — | WO | disclosed |
| CN-110462038-A | Anti- GPRC5D antibody and the molecule comprising the antibody | DAIICHI SANKYO CO LTD | 2019-11-15 | — | — | CN | disclosed |
| WO-2019197607-A1 | FC-ENGINEERED ANTI-HUMAN IGE ANTIBODIES AND METHODS OF USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-10-17 | — | — | WO | disclosed |
| EP-1571919-B2 | NOVEL FOOD PRODUCTION PROCESS | DSM IP ASSETS BV (NL) | 2015-04-15 | — | — | EP | disclosed |
| CN-103374058-B | Solid-phase synthesis process of angiotensinamide as well as intermediate and application thereof | SHANGHAI NO 1 BIOCHEMICAL & PHARMACEUTICAL CO LTD | 2015-04-15 | — | — | CN | disclosed |
| CN-103374058-A | Solid-phase synthesis process of angiotensinamide as well as intermediate and application thereof | SHANGHAI NO 1 BIOCHEMICAL & PHARMACEUTICAL CO LTD | 2013-10-30 | — | — | CN | disclosed |
| CN-102241743-A | Process for producing sugar peptide having asparagine sugar chain and the sugar peptide | OTSUKA CHEMICAL CO LTD | 2011-11-16 | — | — | CN | disclosed |
| EP-1571919-B1 | NOVEL FOOD PRODUCTION PROCESS | DSM IP ASSETS BV (NL) | 2009-08-26 | — | — | EP | disclosed |
| CN-1665832-A | Process for producing glycopeptide having asparagine sugar chain and glycopeptide | OTSUKA CHEMICAL CO LTD (JP) | 2005-09-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226598-A1 | A BACILLUS METHYLOTROPHICUS STRAIN AND METHOD OF USING THE STRAIN TO INCREASE DROUGHT RESISTANCE IN A PLANT | AMD1, AHCY, ALAD | ECE1 962/4885ITGB2 4836/4885ICAM1 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.